Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

TY - JOUR

T1 - Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

AU - Henon, C.

AU - Blay, J. Y.

AU - Massard, C.

AU - Mir, O.

AU - Bahleda, R.

AU - Dumont, S.

AU - Postel-Vinay, S.

AU - Adam, J.

AU - Soria, J. C.

AU - Le Cesne, A.

N1 - Funding Information: J-YB: Research support from MSD BMS and Roche. CM: Consultant/Advisory fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. Principal/sub-Investigator of Clinical Trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, Xenco years, Dr Soria has received consultancy fees from AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda. Dr Soria has been a full-time employee of MedImmune/AstraZeneca since September 2017. He is a shareholder of AstraZeneca and Gritston r . OM: Has acted as consultant or board member for Amgen, AstraZeneca, Bayer, Blueprint Medicines, BMS, Eli-Lilly, Incyte, Ipsen, Lundbeck, MSD, Novartis, Pfizer, Roche, Servier, Vifor Pharma, and owns stock from Amplitude Surgical and Transgene. SP-V: Principal/sub-Investigator of Clinical Trials for Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Exelixis, Forma, Gamamabs, Genentech, Inc., Gilead Sciences, Inc., Glaxosmithkline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc., Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Iris Servier, Janssen, Kura Oncology, Kyowa Kirin Pharm, Lilly, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Rigontec Gmbh, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc., Tioma Therapeutics, Inc., Xencor. Research funding from Boehringer Ingelheim, Roche and Merck KGaA for laboratory research projects unrelated to this manuscrip t . Advisory boards for Merck KGaA, Novarti s . Non-financial support (travel paid and congress registration) for attending symposia from AstraZeneca. JA: Consultant/speaker: AstraZeneca, Bayer, BMS, MSD, Roche. J-CS: Over the last 5 e . ALC: Consultancy fees from Pharmamar, Pfizer, Novarti s . All remaining authors (CH, RB and SD) have declared no conflicts of interest.

PY - 2019/8/1

Y1 - 2019/8/1

UR - http://www.scopus.com/inward/record.url?scp=85072733240&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz160

DO - 10.1093/annonc/mdz160

M3 - Letter

C2 - 31114851

AN - SCOPUS:85072733240

SN - 0923-7534

VL - 30

SP - 1401

EP - 1403

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -